TP53 and cancer: Breast cancer [49,50,51,52], C/EBPα-mutant leukemias [17], MYC-driven cancers [53], pancreatic cancer [54,55], p53 gain-of-function mutant cancers [56], colorectal cancer [57,58], neuroblastoma [5,20], hepatocellular carcinoma [59], bladder cancer [60,61], rhabdoid tumors [62], multidrug-resistant cancers [63], and glioblastomas [64] are all cancer settings in which WDR5 inhibition has been proposed as a future therapy.